Azeliragon,
603148-36-3,
TTP488,
UNII-LPU25F15UQ,
LPU25F15UQ,
PF-04494700,
Azeliragon [INN],
Azeliragon [USAN],
Azeliragon (USAN/INN),
GTPL8317,
SCHEMBL1142599,
TTP448,
CHEMBL3989929,
BCP16862,
EX-A1834,
KS-00000M8W,
MFCD11977600,
ZINC38336973,
AKOS026750516,
CS-5117,
DB12689,
SB19818,
1-Propanamine, 3-(4-(2-butyl-1-(4-(4-chlorophenoxy)phenyl)-1H-imidazol-4-yl)phenoxy)-N,N-diethyl-,
AK499424,
AS-49837,
HY-50682,
D11147,
Azeliragon pound PF-04494700 TTP488 pound(c),
1-Propanamine,3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl]phenoxy]-N,N-diethyl-,
3-(4-(2-Butyl-1-(4-(4-chlorophenoxy)phenyl)-1H-imidazol-4-yl)phenoxy)-N,N-diethylpropan-1-amine,
3-[4-[2-Butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-imidazol-4-yl]phenoxy]-N,N-diethyl-1-propanamine,
3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethylpropan-1-amine,
D0MW7B,
TTP-488,
TTP-488),
Alzheimers therapy, TransTech/Pfizer,
Alzheimer'streatment, TransTech/Pfizer,
CID11180124,
PF-4494700,
Alzheimer's therapy (RAGE), Transtech/Pfizer,
Diabetic nephropathy therapy, Transtech/Pfizer,
1-PropanaMine, 3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]-1H-iMidazol-4-yl]phenoxy]-N,N-diethyl-,
3-[4-[2-butyl-1-[4-(4-chlorophenoxy)phenyl]imidazol-4-yl]phenoxy]-N,N-diethyl-propan-1-amine,
na,